EKF Diagnostics (EKF) Competitors

EKF Diagnostics (LON:EKF) and MaxCyte (LON:MXCT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

Does the media favor EKF or MXCT?

In the previous week, EKF Diagnostics' average media sentiment score of 0.00 equaled MaxCyte'saverage media sentiment score.

Company	Overall Sentiment
EKF Diagnostics	Neutral
MaxCyte	Neutral

Which has preferable earnings & valuation, EKF or MXCT?

EKF Diagnostics has higher earnings, but lower revenue than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EKF Diagnostics	£49.91M	1.87	£4.68M	£1.07	19.54
MaxCyte	£57.52M	4.86	-£45.08M	-£27.29	-7.77

Is EKF or MXCT more profitable?

EKF Diagnostics has a net margin of 9.37% compared to MaxCyte's net margin of -78.37%. EKF Diagnostics' return on equity of 7.03% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
EKF Diagnostics	9.37%	7.03%	5.27%
MaxCyte	-78.37%	-16.01%	-11.07%

Do institutionals & insiders have more ownership in EKF or MXCT?

70.3% of EKF Diagnostics shares are held by institutional investors. Comparatively, 70.5% of MaxCyte shares are held by institutional investors. 5.2% of EKF Diagnostics shares are held by insiders. Comparatively, 1.5% of MaxCyte shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Which has more volatility and risk, EKF or MXCT?

EKF Diagnostics has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, MaxCyte has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.

Does the MarketBeat Community believe in EKF or MXCT?

EKF Diagnostics received 174 more outperform votes than MaxCyte when rated by MarketBeat users. Likewise, 76.76% of users gave EKF Diagnostics an outperform vote while only 68.92% of users gave MaxCyte an outperform vote.

Company	Underperform	Outperform
EKF Diagnostics	Outperform Votes 327 76.76%	Underperform Votes 99 23.24%
MaxCyte	Outperform Votes 153 68.92%	Underperform Votes 69 31.08%

Summary

EKF Diagnostics beats MaxCyte on 9 of the 13 factors compared between the two stocks.